A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and 400 mg TID) in Hospitalized Patients With Severe Bacterial Pneumonia or Bacterial Pneumonia With a Poor Response to Other Antimicrobials.

Trial Profile

A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and 400 mg TID) in Hospitalized Patients With Severe Bacterial Pneumonia or Bacterial Pneumonia With a Poor Response to Other Antimicrobials.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia; Nosocomial pneumonia
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Bayer
  • Most Recent Events

    • 26 Apr 2015 Status changed from recruiting to completed as reported by ClimicalTrials.gov record.
    • 16 Sep 2014 Planned number of patients changed from 30 to 46, as reported by ClinicalTrials.gov.
    • 14 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2014 to 1 Apr 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top